HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1

被引：0
|
作者：
Braso-Maristany, F. [1 ]
Griguolo, G. [2 ]
Chic, N. [3 ]
Pare Brunet, L. [3 ]
Galvan, P. [4 ]
Dieci, M. V. [5 ]
Miglietta, F. [6 ]
Giarratano, T. [7 ]
Martinez-Saez, O. [8 ]
Marin, M. [8 ]
Vidal Losada, M. J. [9 ]
Adamo, B. [10 ]
Munoz, M. [11 ]
Vivancos, A. [12 ]
Villagrasa Gonzalez, P. [13 ]
Parker, J. [13 ]
Perou, C. M. [14 ]
Conte, P. F. [15 ]
Prat, A. [16 ]
Guarneri, V. [17 ]
机构：
[1] IDIBAPS Inst Invest Biomed August Pi & Sunyer, Dept Oncol, Barcelona, Spain
[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[3] Reveal Genom SL, Dept Sci, Barcelona, Spain
[4] IDIBAPS August Pi & Sunyer Biomed Res Inst, Dept Med Oncol, Barcelona, Spain
[5] Univ Padua, DiSCOG, Padua, Italy
[6] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol, Padua, Italy
[7] IOV Ist Oncologico Veneto IRCCS, Dept Oncol, Padua, Italy
[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[9] Hosp Clin Barcelona, Breast Canc, Barcelona, Spain
[10] Hosp Clin Prov Barcelona, Breast Canc Dept, Barcelona, Spain
[11] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[12] Vall Hebron Univ sity Hosp, Genom Dept, Barcelona, Spain
[13] UNC, Dept Oncol, Lineberger Canc Ctr, Chapel Hill, NC USA
[14] UNC, Dept Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[15] IOV Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol Dept, Padua, Italy
[16] Hosp Clin Prov Barcelona, Dept Med Oncol, Barcelona, Spain
[17] Univ Padua, Oncol & Gastroenterol Dept, Dept Surg, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.276
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
237P
引用
收藏
页码：S646 / S646
页数：1
相关论文
共 50 条
  • [1] HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
    Braso-Maristany, Fara
    Griguolo, Gaia
    Chic, Nuria
    Pascual, Tomas
    Pare, Laia
    Maues, Julia
    Galvan, Patricia
    Dieci, Maria Vittoria
    Miglietta, Federica
    Giarratano, Tommaso
    Martinez-Saez, Olga
    Marin-Aguilera, Mercedes
    Schettini, Francesco
    Conte, Benedetta
    Angelats, Laura
    Vidal, Maria
    Adamo, Barbara
    Munoz, Montserrat
    Sanfeliu, Esther
    Gonzalez, Blanca
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Conte, PierFranco
    Prat, Aleix
    Guarneri, Valentina
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (03): : 332 - 336
  • [2] RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
    Bertucci, Francois
    de Nonneville, Alexandre
    Finetti, Pascal
    Mamessier, Emilie
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (06): : 762 - 763
  • [3] Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
    Braso-Maristany, Fara
    Pare, Laia
    Villacampa, Guillermo
    Marin-Aguilera, Mercedes
    Spellman, Paul
    Waks, Adrienne
    Krop, Ian
    Sanfeliu, Esther
    Li, Zhequi
    Galvan, Patricia
    Hernandez-Illan, Eva
    Jares, Pedro
    Puig-Butille, Joan Anton
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Tolaney, Sara
    Metzger, Otto
    Polyak, Kornelia
    Prat, Aleix
    CANCER RESEARCH, 2024, 84 (09)
  • [4] HER2DX: Advances in targeted treatment of HER2-positive breast cancer
    Andujar, Juan M. Cejalvo
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2024, 37 (03):
  • [5] Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
    Sanfeliu, Esther
    Braso-Maristany, Fara
    Dieci, Maria Vittoria
    Marin-Aguilera, Mercedes
    Gonzalez-Farre, Blanca
    Griguolo, Gaia
    Pascual, Tomas
    Galvan, Patricia
    Angelats, Laura
    Castillo, Oleguer
    Blasco, Paula
    Sirenko, Valeria
    Jares, Pedro
    Puig-Butille, Joan Anton
    Pare, Laia
    Martinez, Antonio
    Llombart-Cussac, Antonio
    Cortes, Javier
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Prat, Aleix
    Conte, PierFranco
    Guarneri, Valentina
    CANCER RESEARCH, 2023, 83 (05)
  • [6] T-DM1 for HER2-positive metastatic breast cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
  • [7] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [8] HER2DX ERBB2 mRNA assay following trastuzumab-based chemotherapy in HER2-positive (HER2+) advanced gastric cancer (AGC)
    Sauri Nadal, T.
    Pesantez Coronel, D. S.
    Braso Maristany, F.
    Indacochea, A.
    Cuatrecasas, M.
    Sanfeliu Torres, E.
    Lopezprades, S.
    Candia, L.
    Fernandez-Esparrach, G.
    Mendez, I.
    Nogue Aliguer, M.
    Momblan, D.
    Angelats, L.
    Pascual, T.
    Prat, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S194 - S194
  • [9] Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
    Marin-Aguilera, M.
    Jares, P.
    Sanfeliu, E.
    Villacampa, G.
    Hernandez-lllan, E.
    Martinez-Puchol, A. I.
    Shankar, S.
    Gonzalez-Farre, B.
    Waks, A. G.
    Braso-Maristany, F.
    Pardo, F.
    Manning, D. K.
    Abery, J. A.
    Curaba, J.
    Moon, L.
    Gordon, O.
    Galvan, P.
    Wachirakantapong, P.
    Castillo, O.
    Nee, C. M.
    Blasco, P.
    Senevirathne, T. H.
    Sirenko, V.
    Martinez-Saez, O.
    Aguirre, A.
    Krop, I. E.
    Li, Z.
    Spellman, P.
    Metzger Filho, O.
    Polyak, K.
    Michaels, P.
    Puig-Butille, J. A.
    Vivancos, A.
    Matito, J.
    Buckingham, W.
    Perou, C. M.
    Villagrasa-Gonzalez, P.
    Prat, A.
    Parker, J. S.
    Pare, L.
    ESMO OPEN, 2024, 9 (03)
  • [10] Application and challenge of HER2DX genomic assay in HER2+breast cancer treatment
    Ma, Shujuan
    Zhou, Yan
    Ma, Dandan
    Qi, Xiaowei
    Jiang, Jun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4218 - 4235
12345